Arch Therapeutics Inc. (ARTH) 0.2000 $ARTH
Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Cellulose-Based Hemostatic Agent
Marketwired - Wed Mar 25, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that an independent third party has obtained favorable data from a preclinical animal study that compared the hemostatic activity of AC5 with a popular and commercially available branded absorbable hemostatic agent.
Arch Therapeutics Announces Positive Safety Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Toxicity Studies
Marketwired - Mon Mar 23, 7:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, obtained additional favorable preclinical data from two (2) planned standardized medical device safety studies in which AC5 was assessed for toxicity to cells and for contamination from pyrogens (toxins that cause fever) produced by bacterial cells. The tests are major components of the panel of biocompatibility testing that medical devices must typically complete successfully prior to use in humans.
Nanomedicine: Nanotechnology, Biology, and Medicine Publishes Preclinical Data on Arch Therapeutics' AC5 Surgical Hemostatic Device(TM)
Marketwired - Thu Feb 19, 7:57AM CST
Positive data from an independent third-party research group study sponsored by Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), was published in the peer-reviewed journal Nanomedicine: Nanotechnology, Biology, and Medicine. The results in the manuscript, titled "AC5 Surgical Hemostat(TM) as an Effective Hemostatic Agent in an Anticoagulated Rat Liver Punch Biopsy Model," show that AC5(TM) is agnostic to the presence of the anticoagulant heparin in animals. The abstract can be accessed online here: http://www.nanomedjournal.com/article/S1549-9...8/abstract.
The British Standards Institution Classifies Arch Therapeutics' AC5(TM) as a Medical Device Within the European Union
Marketwired - Tue Feb 17, 7:03AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a medical device company and developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has received confirmation from The British Standards Institution (BSI), a Notified Body in the European Union (EU), that AC5 fulfills the definition of a medical device within the EU and will be classified as such in consideration for CE mark designation. Eventually obtaining the CE mark for AC5 would allow the Company to sell the product within the EU.
Arch Therapeutics Obtains Additional Positive Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Safety Study
Marketwired - Tue Jan 13, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), obtained positive results when AC5(TM) was subjected to a standardized medical device test for irritation potential. The irritation test in animals is a major component of the International Organization for Standardization's (ISO) required panel of biocompatibility testing necessary for medical devices prior to use in humans. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.
Arch Therapeutics Announces Positive Results for AC5 Surgical Hemostatic Device(TM) in Biochemical and Cell Function Safety Studies
Marketwired - Tue Jan 06, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), obtained positive results from preclinical tests in which AC5(TM) was subjected to a battery of high-throughput in vitro safety assessments for biological interactions in standardized testing panels of receptors on the surface of cells and protein kinase enzymes inside cells. These receptors and enzymes represent important biochemical "switches," and interactions with them could indicate biological activity with the potential for toxicity. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.
Arch Therapeutics to Present at The Biotech Showcase(TM) 2015 Conference on January 14th 2015
Marketwired - Wed Dec 17, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at The Biotech Showcase(TM) 2015 Conference on Wednesday, January 14, 2015 at 11:00 AM PST. The conference will be held at the Parc 55 Wyndham Hotel, located at Union Square, San Francisco, California.
ARTH Developing Next Generation Biopharma Product in a $5 Billion Market with Plans for Product Launch in 2015
M2 - Wed Dec 10, 7:13AM CST
ARTH's Flagship product AC5(TM) stops bleeding promptly, even in the presence of blood thinners based on animal data to date. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision.
Arch Therapeutics to Present at LD Micro Main Event on December 4th 2014
Marketwired - Mon Nov 24, 3:00PM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at the LD Micro conference on Thursday, December 4, 2014 at 12:00 PM EST. The conference will be held at the Luxe Sunset Hotel in Bel Air, California.
Arch Therapeutics Reports Positive Preclinical Data from Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated with Brilinta(R) (ticagrelor)
Marketwired - Wed Nov 19, 3:26PM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostat Device(TM), announced that an independent third party has obtained positive data from a preclinical study assessing the use of AC5(TM) in animals that had been treated with orally administered therapeutic doses of the blood thinner ticagrelor, which is currently marketed under the brand name Brilinta(R). The results of the study are consistent with separate data obtained from two recently completed preclinical studies in which AC5 quickly stopped bleeding from surgical wounds created in rats following treatment with clinically relevant doses of the anticoagulant medication heparin; and another preclinical study which reported similar results with respect to the antiplatelet medications Plavix(R) (clopidogrel) and aspirin when used individually and in combination. Anticoagulant and antiplatelet medications are commonly referred to as "blood thinners."
Arch Therapeutics Will Present at Two Investor Conferences in November
Marketwired - Mon Nov 10, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at two conferences in November: SeeThruEquity Microcap Investor Conference and Drexel Hamilton Micro-Cap Investor Forum.
Arch Therapeutics Reports Positive Preclinical Data From Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated With the Antiplatelet Medications Plavix(R) (Clopidogrel) and Aspirin
Marketwired - Thu Nov 06, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostat Device (TM), announced that an independent third-party research group has obtained positive data from a preclinical study assessing the use of AC5(TM) in animals that had been treated with therapeutic doses of the antiplatelet medications Plavix(R) (clopidogrel) and aspirin alone and in combination. The results of the study are consistent with recent data obtained from two previous preclinical studies, in which AC5 quickly stopped bleeding from surgical wounds created in rats following treatment with clinically relevant doses of the anticoagulant medication heparin. Antiplatelet and anticoagulant medications are commonly referred to as "blood thinners."
SeeThruEquity Initiates Research Coverage on Arch Therapeutics with a Target Price of $1.50
ACCESSWIRE - Wed Nov 05, 8:06AM CST
New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Arch Therapeutics, Inc. (OTCQB: ARTH) with a price target of $1.50.
Arch Therapeutics Negotiating a Collaboration Agreement With CURAM Centre for Research in Medical Devices
Marketwired - Thu Oct 23, 7:16AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostat(TM), announced today that it is negotiating a potential collaboration agreement with CURAM Centre for Research in Medical Devices ("CURAM" . CURAM is a major new national research center being established at the National University of Ireland Galway (NUIG) in Galway, Ireland, as part of a six-year grant from the Irish government, which was announced this week. Proceeds, which are expected to be released by the Irish government in January 2015, are intended to fund collaborative work performed by CURAM and its planned industry partners which, subject to the execution of a definitive collaboration agreement, would include Arch. Industry partners, which will benefit by provision of highly skilled personnel, significant grant funding, and available infrastructure support, will provide capital to match a portion of the government funds designated for their respective R&D programs.
Arch Therapeutics Will Present at the Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014
Marketwire - Tue Sep 30, 7:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostat(TM), announced that it will be featured as a presenting company at the 7th Annual Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014 at the Cira Center in Philadelphia, PA.
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th International Conference on Neuroprotective Agents on September 29
Marketwire - Tue Sep 23, 7:51AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) for potential use in bleeding during surgery, announces that co-founder and inventing scientist Dr. Rutledge Ellis-Behnke will present his work using AC5 Surgical Hemostat(TM) at the 12th International Conference on Neuroprotective Agents (ICNA). The ICNA is being held September 29 - October 1, 2014, at the Boar's Head Inn, Charlottesville, VA.
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th Annual Current Issues in Medicine, Biotech and Pharma Conference on September 18
Marketwire - Tue Sep 16, 10:21AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) for potential use in bleeding during surgery, announces that co-founder, inventing scientist and advisor Dr. Rutledge Ellis-Behnke will present research involving AC5(TM) at the 12th Annual Current Issues in Medicine, Biotech and Pharma Conference at Rensselaer Polytechnic Institute in Troy, NY on Thursday, September 18.
Arch Therapeutics Announces Positive Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinners
Marketwire - Mon Sep 08, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), announced that an independent third-party research group has obtained positive data from a preclinical study assessing the use of AC5(TM) in animals receiving an anticoagulant medication (i.e. blood thinner). These results were consistent with the results obtained from a recently completed Arch study that showed that AC5 quickly stopped bleeding from surgical wounds created in the livers of rats that had been treated with a clinically relevant dose of the drug heparin.
Arch Therapeutics Will Present at the 2014 Aegis Capital Healthcare Conference in Las Vegas, NV September 10-13th, 2014
Marketwire - Tue Sep 02, 6:58AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" today announced it will be featured as a presenting company at the 2014 Aegis Capital Healthcare Conference. The presentation will take place at 11:25am PDT on Friday, September 12th at The Encore at Wynn in Las Vegas, NV.
Arch Therapeutics Will Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
Marketwire - Tue Aug 26, 6:58AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City.
Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Cellulose-Based Hemostatic Agent
Marketwired - Wed Mar 25, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that an independent third party has obtained favorable data from a preclinical animal study that compared the hemostatic activity of AC5 with a popular and commercially available branded absorbable hemostatic agent. Arch Therapeutics Announces Positive Safety Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Toxicity Studies
Marketwired - Mon Mar 23, 7:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, obtained additional favorable preclinical data from two (2) planned standardized medical device safety studies in which AC5 was assessed for toxicity to cells and for contamination from pyrogens (toxins that cause fever) produced by bacterial cells. The tests are major components of the panel of biocompatibility testing that medical devices must typically complete successfully prior to use in humans. Nanomedicine: Nanotechnology, Biology, and Medicine Publishes Preclinical Data on Arch Therapeutics' AC5 Surgical Hemostatic Device(TM)
Marketwired - Thu Feb 19, 7:57AM CST
Positive data from an independent third-party research group study sponsored by Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), was published in the peer-reviewed journal Nanomedicine: Nanotechnology, Biology, and Medicine. The results in the manuscript, titled "AC5 Surgical Hemostat(TM) as an Effective Hemostatic Agent in an Anticoagulated Rat Liver Punch Biopsy Model," show that AC5(TM) is agnostic to the presence of the anticoagulant heparin in animals. The abstract can be accessed online here: http://www.nanomedjournal.com/article/S1549-9...8/abstract. The British Standards Institution Classifies Arch Therapeutics' AC5(TM) as a Medical Device Within the European Union
Marketwired - Tue Feb 17, 7:03AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a medical device company and developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has received confirmation from The British Standards Institution (BSI), a Notified Body in the European Union (EU), that AC5 fulfills the definition of a medical device within the EU and will be classified as such in consideration for CE mark designation. Eventually obtaining the CE mark for AC5 would allow the Company to sell the product within the EU. Arch Therapeutics Obtains Additional Positive Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Safety Study
Marketwired - Tue Jan 13, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), obtained positive results when AC5(TM) was subjected to a standardized medical device test for irritation potential. The irritation test in animals is a major component of the International Organization for Standardization's (ISO) required panel of biocompatibility testing necessary for medical devices prior to use in humans. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care. Arch Therapeutics Announces Positive Results for AC5 Surgical Hemostatic Device(TM) in Biochemical and Cell Function Safety Studies
Marketwired - Tue Jan 06, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), obtained positive results from preclinical tests in which AC5(TM) was subjected to a battery of high-throughput in vitro safety assessments for biological interactions in standardized testing panels of receptors on the surface of cells and protein kinase enzymes inside cells. These receptors and enzymes represent important biochemical "switches," and interactions with them could indicate biological activity with the potential for toxicity. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care. Arch Therapeutics to Present at The Biotech Showcase(TM) 2015 Conference on January 14th 2015
Marketwired - Wed Dec 17, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at The Biotech Showcase(TM) 2015 Conference on Wednesday, January 14, 2015 at 11:00 AM PST. The conference will be held at the Parc 55 Wyndham Hotel, located at Union Square, San Francisco, California. ARTH Developing Next Generation Biopharma Product in a $5 Billion Market with Plans for Product Launch in 2015
M2 - Wed Dec 10, 7:13AM CST
ARTH's Flagship product AC5(TM) stops bleeding promptly, even in the presence of blood thinners based on animal data to date. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision.
Arch Therapeutics to Present at LD Micro Main Event on December 4th 2014
Marketwired - Mon Nov 24, 3:00PM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at the LD Micro conference on Thursday, December 4, 2014 at 12:00 PM EST. The conference will be held at the Luxe Sunset Hotel in Bel Air, California. Arch Therapeutics Reports Positive Preclinical Data from Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated with Brilinta(R) (ticagrelor)
Marketwired - Wed Nov 19, 3:26PM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostat Device(TM), announced that an independent third party has obtained positive data from a preclinical study assessing the use of AC5(TM) in animals that had been treated with orally administered therapeutic doses of the blood thinner ticagrelor, which is currently marketed under the brand name Brilinta(R). The results of the study are consistent with separate data obtained from two recently completed preclinical studies in which AC5 quickly stopped bleeding from surgical wounds created in rats following treatment with clinically relevant doses of the anticoagulant medication heparin; and another preclinical study which reported similar results with respect to the antiplatelet medications Plavix(R) (clopidogrel) and aspirin when used individually and in combination. Anticoagulant and antiplatelet medications are commonly referred to as "blood thinners." Arch Therapeutics Will Present at Two Investor Conferences in November
Marketwired - Mon Nov 10, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at two conferences in November: SeeThruEquity Microcap Investor Conference and Drexel Hamilton Micro-Cap Investor Forum. Arch Therapeutics Reports Positive Preclinical Data From Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated With the Antiplatelet Medications Plavix(R) (Clopidogrel) and Aspirin
Marketwired - Thu Nov 06, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostat Device (TM), announced that an independent third-party research group has obtained positive data from a preclinical study assessing the use of AC5(TM) in animals that had been treated with therapeutic doses of the antiplatelet medications Plavix(R) (clopidogrel) and aspirin alone and in combination. The results of the study are consistent with recent data obtained from two previous preclinical studies, in which AC5 quickly stopped bleeding from surgical wounds created in rats following treatment with clinically relevant doses of the anticoagulant medication heparin. Antiplatelet and anticoagulant medications are commonly referred to as "blood thinners." SeeThruEquity Initiates Research Coverage on Arch Therapeutics with a Target Price of $1.50
ACCESSWIRE - Wed Nov 05, 8:06AM CST
New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Arch Therapeutics, Inc. (OTCQB: ARTH) with a price target of $1.50.
Arch Therapeutics Negotiating a Collaboration Agreement With CURAM Centre for Research in Medical Devices
Marketwired - Thu Oct 23, 7:16AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostat(TM), announced today that it is negotiating a potential collaboration agreement with CURAM Centre for Research in Medical Devices ("CURAM" . CURAM is a major new national research center being established at the National University of Ireland Galway (NUIG) in Galway, Ireland, as part of a six-year grant from the Irish government, which was announced this week. Proceeds, which are expected to be released by the Irish government in January 2015, are intended to fund collaborative work performed by CURAM and its planned industry partners which, subject to the execution of a definitive collaboration agreement, would include Arch. Industry partners, which will benefit by provision of highly skilled personnel, significant grant funding, and available infrastructure support, will provide capital to match a portion of the government funds designated for their respective R&D programs. Arch Therapeutics Will Present at the Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014
Marketwire - Tue Sep 30, 7:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostat(TM), announced that it will be featured as a presenting company at the 7th Annual Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014 at the Cira Center in Philadelphia, PA. Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th International Conference on Neuroprotective Agents on September 29
Marketwire - Tue Sep 23, 7:51AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) for potential use in bleeding during surgery, announces that co-founder and inventing scientist Dr. Rutledge Ellis-Behnke will present his work using AC5 Surgical Hemostat(TM) at the 12th International Conference on Neuroprotective Agents (ICNA). The ICNA is being held September 29 - October 1, 2014, at the Boar's Head Inn, Charlottesville, VA. Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th Annual Current Issues in Medicine, Biotech and Pharma Conference on September 18
Marketwire - Tue Sep 16, 10:21AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) for potential use in bleeding during surgery, announces that co-founder, inventing scientist and advisor Dr. Rutledge Ellis-Behnke will present research involving AC5(TM) at the 12th Annual Current Issues in Medicine, Biotech and Pharma Conference at Rensselaer Polytechnic Institute in Troy, NY on Thursday, September 18. Arch Therapeutics Announces Positive Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinners
Marketwire - Mon Sep 08, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), announced that an independent third-party research group has obtained positive data from a preclinical study assessing the use of AC5(TM) in animals receiving an anticoagulant medication (i.e. blood thinner). These results were consistent with the results obtained from a recently completed Arch study that showed that AC5 quickly stopped bleeding from surgical wounds created in the livers of rats that had been treated with a clinically relevant dose of the drug heparin. Arch Therapeutics Will Present at the 2014 Aegis Capital Healthcare Conference in Las Vegas, NV September 10-13th, 2014
Marketwire - Tue Sep 02, 6:58AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
today announced it will be featured as a presenting company at the 2014 Aegis Capital Healthcare Conference. The presentation will take place at 11:25am PDT on Friday, September 12th at The Encore at Wynn in Las Vegas, NV. Arch Therapeutics Will Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
Marketwire - Tue Aug 26, 6:58AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City. 
